HC Wainwright reaffirmed their buy rating on shares of Entrada Therapeutics (NASDAQ:TRDA – Free Report) in a research report report published on Friday, Benzinga reports. They currently have a $25.00 price target on the stock. Entrada Therapeutics Stock Performance Entrada Therapeutics stock opened at $14.42 on Friday. Entrada Therapeutics has a fifty-two week low of […]
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CEO Dipal Doshi sold 1,000 shares of Entrada Therapeutics stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $15.00, for a total value of $15,000.00. Following the completion of the transaction, the chief executive officer now owns […]
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CEO Dipal Doshi sold 1,000 shares of the stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $15.00, for a total value of $15,000.00. Following the transaction, the chief executive officer now owns 248,279 shares of the […]
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CFO Kory James Wentworth sold 950 shares of the company’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $13.48, for a total transaction of $12,806.00. Following the completion of the transaction, the chief financial officer now owns 49,571 […]
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) COO Nathan J. Dowden sold 972 shares of Entrada Therapeutics stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $13.47, for a total transaction of $13,092.84. Following the sale, the chief operating officer now owns 48,168 shares of the […]